Scrip 100: The Architecture Of A Top Heavy Industry
Executive Summary
Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.
You may also be interested in...
Asia 100: Operating Profit Returns To Asian Pharma Sector
Scrip Asia 100 companies showed a return to greater operating profitability for financial year 2015 despite reduced overall dollar-denominated pharmaceutical sales.
INFOGRAPHIC: Asia 100 By The Numbers
Based on full year 2015 pharma sales data, Scrip has crunched the numbers for pharmaceutical
Scrip 100: What It Takes To Sell $724bn-Worth Of Drugs
The Scrip 100 is a story of fallers and risers and a changing helicopter view of the pharmaceutical industry. Data alone cannot predict individual transactions or the fates of particular pharmaceutical products. However, they do paint a clear picture of the nature of the industry and the commercial environment that companies face.